Police seize €57 million in illegal Ozempic, peptides, and other black market drugs in global bust
Between December and May, authorities in 90 countries – including 16 in the European Union – confiscated 50.4 million doses of drugs that were either fake, misbranded, unapproved, or diverted, according to the International Criminal Police Organization (Interpol), which coordinated the operation.
In Europe, many of the seizures were for counterfeit or unapproved weight loss drugs and peptide supplements, which Interpol said reflects the surging popularity of 'cosmetic and performance-enhancing' pharmaceuticals.
These drugs are so widely available online and on social media that police are having a hard time keeping up, Alfonso Mejuto Rodríguez, Interpol's pro tempore assistant director of criminal networks, told Euronews Health.
Related
Rising deaths, fake pills, gang violence: How the EU is struggling to cope with illegal drug problem
'It's not even necessary to go to the dark web [because] there are a lot of advertisements online,' Rodríguez said.
The drugs are marketed as 'good for your health, good for your image,' he added. 'That is exactly the risk for human health, because when you buy them, you are not really sure what they contain'.
The World Health Organization (WHO) and European Medicines Agency (EMA) have both warned in recent years that the black market is flourishing for counterfeit semaglutide, which is the active ingredient in blockbuster anti-obesity and diabetes medicines such as Ozempic and Wegovy.
Interpol said a single semaglutide pen can sell for hundreds of euros on the black market.
Meanwhile, peptide seizures were relatively rare until recently. The agency said the uptick in Europe, North America, and Oceania reflects a rise in demand for supplements such as BPC-157, ipamorelin, and melanotan, which are unproven products sold illegally as wellness, anti-ageing, or cosmetic aids.
Related
Weight loss drugs: New study sheds light on illegal online pharmacies selling Wegovy and Ozempic
Melanotan, for example, is a synthetic hormone designed to boost melanin production, giving people the appearance of tanned skin. Sometimes called the 'Barbie drug,' melanotan has taken off on platforms such as TikTok – but it is not regulated in Europe and health agencies have warned that it may cause serious health problems.
'With a lot of substances, the marketing is amplified by influencers, for instance in terms of health and culture,' Rodríguez said.
Worldwide, the most commonly seized illicit pharmaceuticals were psychostimulants, anti-anxiety drugs, and Parkinson's disease medicines, followed by erectile dysfunction drugs, Interpol said.
Other commonly seized counterfeit or otherwise illegal drugs include anabolic steroids, anti-smoking medicines, dermatological agents, health supplements, herbal products, and psychotropic medications for mental health conditions.
Police also confiscated the opioid painkiller oxycodone in Bulgaria, France, Ireland, and Sweden.
Related
Fake painkillers are circulating in the Netherlands, authorities warn after man dies
The sale of counterfeit medicines can have deadly consequences. In March, a 30-year-old man died after taking fake painkillers in the Netherlands, and last month, health authorities in Denmark warned that they were also circulating there.
'It seems that in the West, the demand for painkillers is rising… and criminals are taking advantage of it,' Rodríguez said.
As part of the Interpol operation, nearly 800 suspects were arrested and 123 criminal groups were dismantled. Police also took down about 13,000 websites, social media accounts, and bots that advertised and sold illegal or counterfeit medicines online.
Authorities in Ireland shuttered about 1,400 online listings for fake or illegal medicines, more than any other country except for Malaysia and Russia. Together with Singapore and Iran, the five countries accounted for 96 per cent of all listings that were taken down.
Related
Over 230 arrested as Europol dismantles four major drug smuggling networks
Ireland also saw large seizures of illegal medicines, as did the Netherlands, Portugal, Spain, Sweden, and the United Kingdom, according to Interpol.
In Portugal, for example, police discovered anabolic steroids in eight prisons, which Interpol said was evidence of a criminal smuggling network.
The agency noted that Europe-based criminals have easy access to the raw materials and infrastructure needed to run counterfeit drug production networks, meaning they can quickly adapt to changing trends and demand from consumers.
'It's a challenge for law enforcement agencies to follow this activity,' Rodríguez said.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Newsweek
2 hours ago
- Newsweek
Californians Warned of 'Devastating' New Health Insurance Costs
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. Health insurance costs are set to increase for Californians in 2026, and the state's health insurance marketplace has warned that the impacts could be a major burden on American families. This comes as health insurance premiums are expected to rise significantly across the country next year, when enhanced tax credits are set to expire, as President Donald Trump has not chosen to renew them. A spokesperson for Covered California told Newsweek: "The combined impact of the premium increases and the loss of enhanced premium tax credits would be devastating for Californians." "All Covered California enrollees would face higher costs, and the loss of enhanced tax credits alone could result in an average net premium increase of 66 percent for 1.7 million enrollees," they said. The spokesperson called it "a catastrophic financial burden for many, potentially pricing a significant number of individuals and families out of coverage." "Those with the lowest incomes would be hit hardest, as stagnant wages and rising inflation amplify their challenges." Why It Matters Aside from the expiration of enhanced tax credits, which will see 2026's rise in costs jump much higher than previous years, there are also a number of other factors pushing up premiums. These factors include increased health care costs, inflation, labor costs, and rising demand for medications such as GLP-1 drugs like Ozempic and Wegovy, which are driving up prescription drug spending. While premiums have been steadily increasing over the years, 2026 will see the largest hike in prices since 2018, according to KFF data. Agents help sign people up for insurance through the Covered California exchange at their storefront in Huntington Beach, California. Agents help sign people up for insurance through the Covered California exchange at their storefront in Huntington Beach, California. Nick Agro/The Orange County Register via AP What To Know Covered California recently announced that it would be increasing rates for health coverage in 2026 by an average of 10.3 percent across various health plans. Those on Affordable Care Act (ACA)-compliant plans will be affected, as the temporary subsidies for ACA marketplaces, introduced by former President Joe Biden to increase access to health coverage, will expire at the end of 2025. While there is still time for the Trump administration to opt to extend the subsidies, there has been no indication yet by the administration that they intend to, and the subsidies also come at a significant cost to the taxpayer. Covered California told Newsweek that its planned 10.3 percent increase is lower than the national average of 20 percent, with states like Florida having much higher proposed increases. The reason for the state marketplace's increase in premium costs is driven by several factors, the Covered California spokesperson told Newsweek, pointing to "rising health care and pharmacy costs, as well as broader industry challenges." They said that federal health care policies were also "contributing to these increases, particularly the expiration of federal enhanced premium tax credits at the end of 2025." "These credits have helped millions of Americans lower their premiums since 2021, and their expiration will have significant consequences for affordability nationwide," they said. The state marketplace previously said that Congress could reduce these price hikes for Americans by extending the enhanced tax credits, and that it hoped lawmakers on both sides of the aisle "recognize the need to extend this essential lifeline for working families." What People Are Saying A spokesperson for Covered California told Newsweek: "To mitigate these impacts, California is taking proactive steps to shield its lowest-income enrollees from steep increases. For 2026, the state has allocated $190 million from its cost-sharing reduction program to provide state subsidies for individuals earning up to 150 percent of the federal poverty level, helping keep premiums comparable to 2025 levels. "This assistance will benefit individuals with annual incomes of $23,475 or less and families of four earning up to $48,225. Additional support will also be available to those earning up to 165 percent of the federal poverty level." Jonathan Gruber, a professor of economics at Massachusetts Institute of Technology, told Newsweek: "Rates are certainly going to go up because of two changes: the [One Big Beautiful Bill] kicks some folks off exchanges and makes it harder for others to enroll and the additional subsidies that President Biden added to the exchanges are going to expire. When these changes happen it is the healthiest folks who will drop out of the exchanges, raising premiums for everyone else." He added, "This is disastrous for both economic security and health. Studies have shown that losing insurance is associated with enormous economic risk and worse health, including death." Ge Bai, a professor of health policy and management at Johns Hopkins Bloomberg School of Public Health, Maryland, told Newsweek: "ACA-compliant plans have always been expensive, but the federal government has made them appear affordable through taxpayer subsidies. The premiums we see now reflect their actual unaffordability, rather than the artificial affordability created by subsidies." She said: "While market characteristics may cause some state-to-state variations, the overall trend will be upward everywhere because the regulatory constraints driving up costs apply to ACA-compliant plans in all states." "ACA-compliant plans will become more expensive, especially for higher-income beneficiaries who lose subsidy eligibility. We urgently need to address the ACA's regulatory constraints that block affordable plans, rather than pouring taxpayer dollars into creating the illusion of affordability and worsening these plans' true unaffordability." What Happens Next The proposed increases are for the 2026 calendar year, and many are concerned about the impacts they will have on Americans.
Yahoo
6 hours ago
- Yahoo
Mounjaro price increase sees patients switch to cheaper Wegovy
Following news that the manufacturer price for Mounjaro will be increasing by 170%, pharmacies have been inundated by people looking to switch to Wegovy. Google Trends shows a +5,500% increase for 'can I swap from Mounjaro to Wegovy' since last Thursday, highlighting that people in the UK and Northern Ireland are searching for a more cost-effective treatment to continue their weight loss journey. There has also been issues with some pharmacies running out of stock of Moumjaro, as patients try to get supplies before the price hike. Mounjaro users report surprising side effect - pharmacists share their tips — Bucks Free Press (@bucksfreepress) August 8, 2025 'With Mounjaro's price rise looming, it's not surprising that patients are exploring alternatives," says Jason Murphy, Head of Pharmacy at Chemist4U. "Wegovy offers a safe, less expensive and almost equally effective weight loss solution and is a very good option to consider if Mounjaro becomes unaffordable. 'However, switching should always be as part of a conversation with your pharmacist or GP. Our role is to guide patients through the process, tailoring advice to their health history, so they can continue their weight loss journey with confidence.' Both medications are part of a group called GLP-1 receptor agonists What is Wegovy? Is it the same as Ozempic? Wegovy and Mounjaro are both weekly injections originally designed for type 2 diabetes but are powerful weight-loss drugs. Wegovy (the brand name for semaglutide) works by mimicking a gut hormone (GLP-1) that curbs appetite and slows digestion. Semaglutide is also branded as Ozempic for managing type 2 diabetes, but is not prescribed for weight-loss in the UK. Mounjaro goes a step further by also targeting a second hormone, GIP. 'When moving from Mounjaro to Wegovy, it's not a one-size-fits-all process," says Jason. "Your starting Wegovy dose should always reflect the Mounjaro dose you were previously on, alongside your overall health, and how well you tolerated treatment. That's why a pharmacist's review is essential; it ensures the transition is safe, effective, and tailored to your individual needs.' Who is eligible for Wegovy? For those who have not taken a weight loss injection before, Wegovy has the same eligibility criteria as Mounjaro. This means a BMI of 30 or higher, or a BMI of 27 or higher with a pre-existing medical condition that is affected by weight (e.g., cardiovascular disease or high blood pressure). This might be more complicated for patients who have already lost weight on Mounjaro and are now below a BMI of 30, or 27, and now looking to continue their weight-loss, but experts recommend speaking a doctor or pharmacist. How do you switch from Mounjaro to Wegovy? Jason says that when switching, it's important to not stop Mounjaro until your prescriber confirms the switch to Wegovy is possible. But, he cautions: 'Please note that the manufacturer recommends leaving 30 days from your last dose of Mounjaro and your first dose of Wegovy, to further reduce the risk of side effects, however we understand this could result in stalling your weight loss journey or potential weight gain.' He adds that if you've already lost weight while taking Mounjaro, or are using it to maintain your weight, and are now below the eligibility criteria, you may still be able to switch to Wegovy; a clinical team will review your medical history and decide if it's safe and suitable. Recommended reading: When will Mounjaro be rolled out on the NHS? Why am I not losing weight on Mounjaro? Users' questions answered. Mounjaro 'golden dose' revealed in new survey What are the Wegovy and Mounjaro side effects? People respond to medications in different ways, and even though Mounjaro and Wegovy share similar ingredients, some people may tolerate one better than another. Jason adds: 'There are no 'withdrawal' symptoms in the usual sense. Some people notice their appetite increases as the medicine wears off, and any side effects usually settle after stopping. If you feel unwell or are unsure what to expect, speak to your prescriber. 'It's unlikely you'll gain weight when switching, as the effects of Mounjaro will continue during the seven days after your final dose. You will then immediately start taking Wegovy, which will continue to work in the same way. This means you can continue losing weight while switching, especially if you're sticking to your diet and exercise plan.'
Yahoo
7 hours ago
- Yahoo
Ozempic creator Novo Nordisk will sell weight loss drugs for cheaper through this new partnership
Ozempic creator Novo Nordisk will sell weight loss drugs for cheaper through this new partnership originally appeared on TheStreet. Telemedicine company GoodRx () has been helping Americans find the cheapest way to buy drugs for years. Thanks to a new partnership with pharma giant Novo Nordisk () , the creator of Ozempic and Wegovy, it might soon be the cheapest way to buy branded weight loss drugs too. On Monday, the two firms announced a partnership which will allow patients with a prescription to get the branded medication for $499/mo, so long as they're willing to pay out of pocket and present the GoodRx coupon at their local pharmacy. At $499/mo the branded drug is only a little more expensive than compounded GLP-1 injectables sold by telehealth pharmacies, which have drawn the ire of pharmaceutical giants and the Food and Drug Administration (FDA). It's also more expensive than the $349/mo single-dose vial of Zepbound, the competing GLP-1 drug sold by competitor Eli Lilly () , which is also available through GoodRx. However, Ozempic and Wegovy's patented pens might be reason enough to pay up, since they're easier to use. Still, those with insurance might be eligible to have the cost completely covered, rather than pay the out of pocket cost. For that, patients should check with their prescriber and insurer. This is not Novo's first ride on the direct-to-consumer wagon. In April, it partnered with Hims & Hers HIMS (-1%) to help them sell Wegovy directly to customers. Novo ended that effort in July, alleging that the telehealth company intentionally undercut their branded medications through "deceptive promotion and selling of illegitimate, knockoff versions" of its drug, which "put patient safety at risk." A lawsuit has been filed against Hims & Hers. The failed "collaboration" between the companies spurred the departure of its chief executive, as well as a reduction to the company's annual guidance ahead of its quarterly earnings. Worst of all, it say Novo Nordisk lose market share to competitor Eli Lilly, which represents over half of the GLP-1 market. Novo's leadership have indicated a desire to expand its direct-to-consumer offerings and cut prices, looking to undercut both branded and compounded GLP-1 drugs. Ozempic creator Novo Nordisk will sell weight loss drugs for cheaper through this new partnership first appeared on TheStreet on Aug 18, 2025 This story was originally reported by TheStreet on Aug 18, 2025, where it first appeared.
